

similar altered markers (although with different magnitude effect) in schizophrenia and schizotypy.

---

### **SP01. Human rights and psychiatric treatment: a round table of concerned partners**

*Chair:* P. Cosyns (B)

*Participants:*

Jean Claus, Council of Europe (F)

Jean Canneva, UNAFAM (F)

Paul Cosyns, AEP (B)

Nina Rehnqvist, National Board of Health and Welfare (S)

---



---

### **PL03. Plenary Nobel Laureate Lecture: Molecular biology of memory and its disorders**

*Introduction by:* Sten Grillner (S)

---

#### **PL03**

Molecular biology of memory and its disorders

E.R. Kandel\*. *Columbia University College of Physicians & Surgeons, Senior Investigator, Howard Hughes Medical Institute, USA*

I will consider the molecular mechanisms whereby a transient short-term memory is converted into a stable, self-maintained, long-term memory. I will first outline studies in *Aplysia* and mice that show this conversion from short to long-term memory requires protein synthesis and this protein synthesis is reflected, on the cellular level, in the activation of a cascade of genes, that leads to the growth of new synaptic connections. Second, I will go on to consider mouse models of clinical defects in converting short to long-term hippocampal based memory, in particular age-related memory loss and Down's syndrome.

---

### **LS05. Health economics and schizophrenia (Sponsored by Eli Lilly, Sweden)**

*Chair:* N. Sartorius (CH)

---

#### **LS05.1**

Introduction to health economics: terminology and concepts – types of economic evaluations. Choice perspective. Cost components. Markov models

L. Jönssen. *Sweden*

No abstract was available at the time of printing.

#### **LS05.2**

Ethical aspects – who should have the right to treatment

S. Thelander. *Sweden*

No abstract was available at the time of printing.

#### **LS05.3**

Health economic evaluations in schizophrenia

M. Knapp. *UK*

No abstract was available at the time of printing.

---

### **LS06. Insights, promise, and renewed hope in the treatment of schizophrenia (Sponsored by Bristol-Myers Squibb)**

*Chairs:* L. Farde (S), M. Bourin (F)

---

#### **LS06.1**

Welcome and introduction

L. Farde. *Sweden*

No abstract was available at the time of printing.

#### **LS06.2**

Schizophrenia: a chronic illness seeking a long-term solution

R.S. Kahn. *The Netherlands*

No abstract was available at the time of printing.

#### **LS06.3**

Stabilizing the dopamine-serotonin system: a new goal in the management of schizophrenia

L. Farde. *Sweden*

No abstract was available at the time of printing.

#### **LS06.4**

Antipsychotic effect and clinical benefit in the management of schizophrenia

M. Bourin. *France*

No abstract was available at the time of printing.

#### **LS06.5**

Safety, tolerability and compliance in the use of antipsychotics

W.W. Fleischhacker. *Austria*

No abstract was available at the time of printing.